Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose their characteristics and acquire mesenchymal traits to promote cell movement. This program is aberrantly activated in human cancers and endows tumor cells with increased abilities in tumor initiation, cell migration, invasion, metastasis, and therapy resistance. The EMT program in tumors is rarely binary and often leads to a series of gradual or intermediate epithelial-mesenchymal states. Functionally, epithelial-mesenchymal plasticity (EMP) improves the fitness of cancer cells during tumor progression and in response to therapies. Here, we discuss the most recent advances in our understanding of the diverse roles of EMP in tumor initiation, progression, metastasis, and therapy resistance and address major clinical challenges due to EMP-driven phenotypic heterogeneity in cancer. Uncovering novel molecular markers and key regulators of EMP in cancer will aid the development of new therapeutic strategies to prevent cancer recurrence and overcome therapy resistance.

Update on Epithelial-Mesenchymal Plasticity in Cancer Progression / Fontana, Rosa; Mestre-Farrera, Aida; Yang, Jing. - In: ANNUAL REVIEW OF PATHOLOGY. - ISSN 1553-4006. - 19:1(2024), pp. 133-156. [10.1146/annurev-pathmechdis-051222-122423]

Update on Epithelial-Mesenchymal Plasticity in Cancer Progression

Fontana, Rosa;
2024

Abstract

Epithelial-mesenchymal transition (EMT) is a cellular process by which epithelial cells lose their characteristics and acquire mesenchymal traits to promote cell movement. This program is aberrantly activated in human cancers and endows tumor cells with increased abilities in tumor initiation, cell migration, invasion, metastasis, and therapy resistance. The EMT program in tumors is rarely binary and often leads to a series of gradual or intermediate epithelial-mesenchymal states. Functionally, epithelial-mesenchymal plasticity (EMP) improves the fitness of cancer cells during tumor progression and in response to therapies. Here, we discuss the most recent advances in our understanding of the diverse roles of EMP in tumor initiation, progression, metastasis, and therapy resistance and address major clinical challenges due to EMP-driven phenotypic heterogeneity in cancer. Uncovering novel molecular markers and key regulators of EMP in cancer will aid the development of new therapeutic strategies to prevent cancer recurrence and overcome therapy resistance.
2024
Update on Epithelial-Mesenchymal Plasticity in Cancer Progression / Fontana, Rosa; Mestre-Farrera, Aida; Yang, Jing. - In: ANNUAL REVIEW OF PATHOLOGY. - ISSN 1553-4006. - 19:1(2024), pp. 133-156. [10.1146/annurev-pathmechdis-051222-122423]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/993999
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 112
  • ???jsp.display-item.citation.isi??? 105
social impact